The role of sibutramine in weight reduction

Abstract

Abstract:Background: The effectiveness of pharmacologic support with sibutramine along with the preservation of dietary and regimen measures is shown in a group of long-term treated patients at the Metabolic Clinic of the University Hospital in Hradec Králové. Methods: In ambulatory patients, basic anthropometric parameters as body weight, BMI, waist circumference and the total amount of adipose tissue were compared before substitution with 10 mg sibutramine and after a four-month therapy. This group included 94 patients who were administered the same dose of sibutramine for the whole period of time. This group consisted of 37 men and 57 women. Results: After a four-month therapy with sibutramine there was a mean reduction in weight by 7.9 ± 3.8 kg in the monitored group of patients. Their BMI was reduced by 2.3 ±1.5 kg/height 2 and the waist circumference by 4.4±3.8 cm. The decrease in the percentage of the total body lipid was 2.9 %. Conclusion: Despite a surprising decision of the European Drug Agency to suspend the registration of sibutramine in the whole of Europe since January 2010 we can state that in our patients we have proven a positive effect of sibutramine substitution on their weight reduction (Tab. 1, Ref. 19 Obesity has become the most frequent metabolic disease as a result of life conditions and lifestyle which have resulted in a positive energetic balance. As far as the number of obese people is concerned Czech Republic is one of the leading EU countries in both, the obesity of men and women (1). The prevalence of obesity and overweight reaches almost 70 % in this country. Obesity represents a severe risk factor which plays an important role in the occurrence of a number of metabolic diseases such as diabetes mellitus, dyslipidemia and atherosclerosis which is manifested as acute myocardial infarction, angina pectoris, ischemic heart disease etc. Obesity has posed a problem to mankind since a very long time. However, at the end of the 20th century it reached the dimension of a global epidemic as a result of constantly increasing energy intake without an adequate increase in energy expenditure (2). Abdominal obesity -a waist circumference of more than 88 cm in women and of more than 102 cm in men is considered the most dangerous form of obesity (3).The treatment of obesity is based on the consistent observance of the diet and exercise regimen (4, 5). Without this consistent observance pharmacotherapy should not be initiated. The aim of the modern pharmacotherapy of obesity is to help the patients to reduce their weight and to maintain it on a long-term basis or to treat the metabolic disorders which predispose the individual to develop obesity. In accordance with the recommendations of the Czech Society for Obesity the pharmacotherapy should be initiated in obese patients in the following cases: -in patients with an initial body mass index (BMI) of more than 30 kg/m 2 if the complex non-pharmacological therapy of obesity failed, that is more than 5 % of weight reduction has not been reached durin...

The role of neurotransmitters in regulation of energy homeostasis and possibility of drug correction of its disturbances in obesity

“…Отсутствие иных эффективных препаратов для лечения ожирения привело к дальнейшим исследованиям препарата, а также пересмотру исследования SCOUTбыла продемонстрирована безопасность применения сибутрамина у пациентов с ССЗ в течение короткого периода лечения (до 6 мес) [22,23], а также безопасность его краткосрочного [24,25] и долгосрочного [26] применения у пациентов, не имеющих в анамнезе ССЗ.…”

Sibutramine: Myths and Realities

“…Также эффективность сибутрамина была оценена на чешской популяции больных в возрасте от 21 до 75 лет [8]. Пациенты принимали сибутрамин в дозе 10 мг в течение 4 месяцев.…”

Development of an HPLC Method for Sibutramine Identification. Search for Undeclared Sibutramine in Biologically Active Additives Appetite Suppressants

“…It belongs to the group of psychotropic drugs for the treatment of obesity and is used in the complex therapy of overweight patients. It is used only as a restrictive measure in a hospital under strict medical supervision [2,4].…”

“…Since 24.01.2008, sibutramine has been included in the list of highly active drugs approved by the Government of the Russian Federation. This means that the sale of sibutramine-containing drugs in pharmacies is allowed only under a special prescription and is subject to special registration [4].…”